

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on April 2, 2026 | For discussion with your oncologist

TRIAL

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT ID: NCT03686124 Phase: PHASE1 / PHASE2 Sponsor: Immutics US, Inc. Status: Recruiting

SUMMARY

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

KEY ELIGIBILITY CRITERIA

- * Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment.
- * Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- * HLA-A*02:01 positive
- * For patients with ovarian/fallopian tube cancer only: Patients must have confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.
- * For patients with endometrial carcinoma only: Patients must have a histologically confirmed diagnosis of recurrent or persistent endometrial carcinoma.
- * Measurable disease according to RECIST 1.1
- * Adequate selected organ function per protocol
- * Patient's tumor must express tumor antigen by "IMADetect® RT-qPCR. Retrospective testing will be required for patients that qualify.
- * Life expectancy more than 5 months
- * Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA203/IMA203CD8

ENROLLMENT CONTACT

Allison Warner, MD

Stanford Cancer Institute

Stanford, California, United States

Email: allison.betof@stanford.edu

Total sites: 19 | 17 currently recruiting